CRISPR Therapeutics AG $CRSP Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 46.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,719 shares of the company’s stock after selling 17,763 shares during the quarter. SG Americas Securities LLC’s holdings in CRISPR Therapeutics were worth $1,343,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of CRSP. Moran Wealth Management LLC lifted its stake in shares of CRISPR Therapeutics by 58.9% in the third quarter. Moran Wealth Management LLC now owns 21,697 shares of the company’s stock worth $1,406,000 after buying an additional 8,043 shares in the last quarter. Abundance Wealth Counselors acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $214,000. Bouvel Investment Partners LLC lifted its stake in CRISPR Therapeutics by 1.9% in the 3rd quarter. Bouvel Investment Partners LLC now owns 31,747 shares of the company’s stock worth $2,058,000 after purchasing an additional 586 shares in the last quarter. D.A. Davidson & CO. acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $349,000. Finally, Western Pacific Wealth Management LP boosted its holdings in shares of CRISPR Therapeutics by 560.0% during the 3rd quarter. Western Pacific Wealth Management LP now owns 3,300 shares of the company’s stock worth $214,000 after purchasing an additional 2,800 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $53.51 on Friday. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The firm has a market cap of $5.10 billion, a PE ratio of -9.57 and a beta of 1.70. The company has a 50-day moving average of $54.71 and a two-hundred day moving average of $58.24.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.15. The company had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Citizens Jmp reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. Wells Fargo & Company set a $75.00 target price on CRISPR Therapeutics in a research note on Monday, October 13th. Wedbush lowered their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, November 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $68.35.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.